JPH01163110A - Preventive for aging of skin - Google Patents
Preventive for aging of skinInfo
- Publication number
- JPH01163110A JPH01163110A JP62323568A JP32356887A JPH01163110A JP H01163110 A JPH01163110 A JP H01163110A JP 62323568 A JP62323568 A JP 62323568A JP 32356887 A JP32356887 A JP 32356887A JP H01163110 A JPH01163110 A JP H01163110A
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- skin
- acid
- aging
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003449 preventive effect Effects 0.000 title claims description 6
- 230000002431 foraging effect Effects 0.000 title 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 78
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 230000009759 skin aging Effects 0.000 claims abstract description 15
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 10
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 10
- 235000013336 milk Nutrition 0.000 claims abstract description 8
- 210000004080 milk Anatomy 0.000 claims abstract description 8
- 239000008267 milk Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Chemical group 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 4
- 150000002632 lipids Chemical class 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 10
- -1 sialic acid salt Chemical class 0.000 abstract description 8
- 238000000746 purification Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000020247 cow milk Nutrition 0.000 abstract description 2
- 235000020256 human milk Nutrition 0.000 abstract description 2
- 210000004251 human milk Anatomy 0.000 abstract description 2
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 235000020254 sheep milk Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000000203 mixture Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000434 stratum corneum Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000007306 turnover Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 206010048218 Xeroderma Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 206010021198 ichthyosis Diseases 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 229940082483 carnauba wax Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 230000008417 skin turnover Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- UMEKPPOFCOUEDT-UHFFFAOYSA-N 1-icosanoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO UMEKPPOFCOUEDT-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 240000006740 Cichorium endivia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 101710199886 Protein 0.5 Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940080284 cetyl sulfate Drugs 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000003733 chicria Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- VLHZUYUOEGBBJB-UHFFFAOYSA-N hydroxy stearic acid Natural products OCCCCCCCCCCCCCCCCCC(O)=O VLHZUYUOEGBBJB-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940113915 isostearyl palmitate Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- YRTWNFXASSUQEW-UHFFFAOYSA-M sodium;methanol;acetate Chemical compound [Na+].OC.CC([O-])=O YRTWNFXASSUQEW-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、皮膚老化予防剤(皮膚の老化予防に用いる)
に関する。詳しくは、皮膚老化予防効果(荒肌改善効果
、角質改善効果、皮膚のターンオーバー速度を速くする
効果、皮膚のくすみ、たるみ、はり、つや、硬化等の改
善効果、皮膚賦活効果、保湿効果等)を有する皮膚老化
予防剤に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention provides a skin aging prevention agent (used for skin aging prevention).
Regarding. In detail, the skin aging prevention effect (improving rough skin, keratin improvement effect, speeding up skin turnover rate, improving skin dullness, sagging, firmness, luster, hardening, etc., skin revitalizing effect, moisturizing effect, etc.) ).
加齢に伴う皮Y9の老化現象(老人に多く見られる現象
)については、−1mに肉眼的にくすみ、シワ、シミが
増加し乾燥した状態になり、それに伴い、いわゆる皮膚
の潤い、ツヤ、滑らかさ、柔らかさ、はり等の減少とい
う機能的な変化を生じることが知られている。又、老人
に高頻度でみられる皮膚疾患(老人に多くみられる病気
)として、老人性色素斑、老人性乾皮症、老人性白斑、
老人性浣贅、老人性神経線維腫、老人性面庖、老人性脂
腺増殖症等が挙げられる。更には癌前駆症(日光角化症
、皮角、Bowen病、悪性黒子)、皮膚感、悪性黒色
腫等の悪性腫瘍が発生してくることが知られている。Regarding the aging phenomenon of skin Y9 (a phenomenon often seen in the elderly) due to aging, the appearance of dullness, wrinkles, and spots increase macroscopically at -1m, and the skin becomes dry, and as a result, the so-called skin moisture, luster, It is known to cause functional changes such as a decrease in smoothness, softness, firmness, etc. In addition, skin diseases that are frequently seen in the elderly (diseases that are often seen in the elderly) include senile pigment spots, senile xeroderma, senile vitiligo,
Examples include senile warts, senile neurofibroma, senile acne, and senile sebaceous gland hyperplasia. Furthermore, it is known that cancer precursors (actinic keratosis, skin horns, Bowen's disease, lentigo maligna), skin irritation, and malignant tumors such as malignant melanoma may occur.
これらの老化現象の要因は■内的要因として、皮脂腺機
能低下、汗腺機能低下、角質層の粗糖化、表皮の非薄化
、コラーゲン架橋増加、不溶性コラーゲン増加、結合組
織基質減少、毛細血管機能低下、代謝機能低下、色素代
謝異常等、■外的要因として、紫外線、低温、低湿条件
等が挙げられる。The causes of these aging phenomena are ■Internal factors include decreased sebaceous gland function, decreased sweat gland function, coarse glycation of the stratum corneum, non-thinning of the epidermis, increased collagen cross-linking, increased insoluble collagen, decreased connective tissue matrix, and decreased capillary function. , decreased metabolic function, abnormal pigment metabolism, etc. External factors include ultraviolet rays, low temperature, low humidity conditions, etc.
老化皮膚の代表的特徴として挙げられる乾燥して滑らか
さのない荒肌は、角質細胞の機能低下が認められ、老化
による皮脂分泌の低下や表皮内(特に角質層)水分結合
物質の量的減少により水分が不足し誘発される症状であ
る。高齢者の場合は、角質層水分含有量が飽和水分量の
10%程度以下になると生じやすい。この症状は特に冬
期の空気が乾燥した時に悪化し、好適な例としては老人
性乾皮症等が挙げられる。Dry, unsmooth, rough skin, which is a typical characteristic of aging skin, is due to a decline in the function of corneocytes, a decrease in sebum secretion due to aging, and a quantitative decrease in water-binding substances in the epidermis (especially in the stratum corneum). This is a symptom caused by a lack of water. In the case of elderly people, it is likely to occur when the water content of the stratum corneum is about 10% or less of the saturated water content. This symptom worsens especially when the air is dry in winter, and a suitable example is senile xeroderma.
このような皮膚がカサカサする現象に対処する為には、
皮膚のターンオーバー(表皮が角質層に変化して剥離し
ていく速度:老化している皮膚は細胞***の速度が低下
しているのでターンオーバーが遅くなる)を高めるとと
もに、皮ita能を正常に維持することが必要であり、
各種の薬剤が医療面及び化粧品領域において開発されて
きた。To deal with this phenomenon of dry skin,
Increases skin turnover (the rate at which the epidermis changes into the stratum corneum and peels off; aging skin has a slower rate of cell division, so turnover slows down) and normalizes the skin's ability to function. It is necessary to maintain
Various drugs have been developed in the medical and cosmetic fields.
−i的な方法としては、ビタミンE剤等の毛細血管拡張
剤やプラセンタリキッド等の呼吸促進剤があり、皮膚の
血行を促進させ代謝を高めることにより改善を促す。ま
た皮膚表面に皮脂類似組成物あるいは保湿剤等を塗布し
、皮膚を被うことにより乾燥を防止する方法等もある。-I methods include capillary dilators such as vitamin E preparations and respiratory stimulants such as placenta liquid, which promote improvement by promoting blood circulation in the skin and increasing metabolism. There is also a method of applying a sebum-like composition or a moisturizing agent to the skin surface and covering the skin to prevent dryness.
しかしながら、前述の毛細血管拡張作用あるいは皮膚呼
吸促進作用による改善作用はいずれも遅効性で、効果発
現までにクリームの場合で速(とも1週間、ローション
の場合では2週間を要し、なかなか十分な満足を得られ
ず改良の余地を残していた。また皮脂類似組成物や保湿
剤は、−時的に角質層中の水分保持に役立つが、その使
用性は悪く油っぽかったりベタベタしたりして、しかも
効果の持続性を高めるためには、使用量く塗布量)を多
くしなければならないという欠点があった。However, the above-mentioned improvement effects due to the telangiectatic effect or the skin respiration promoting effect are slow-acting, and the effect appears quickly in the case of a cream (1 week for both, and 2 weeks for a lotion), so it is difficult to obtain sufficient effects. However, sebum-like compositions and moisturizers sometimes help retain moisture in the stratum corneum, but they are not easy to use and tend to be oily or sticky. Moreover, in order to increase the durability of the effect, the amount used (the amount of application) must be increased.
又、上述以外の老化現象(例えば、しわ、たるみ、しみ
等)に対処する為の薬剤は、有効性及び安全性の点で今
だ満足すべき薬剤が、医療面及び化粧品領域において得
られていない。In addition, drugs for dealing with aging phenomena other than those mentioned above (e.g., wrinkles, sagging, age spots, etc.) have yet to be found in the medical and cosmetic fields, with satisfactory efficacy and safety. do not have.
本発明者らは、上記の事情に鑑み、老化現象に対して有
効でかつ安全性の高い薬剤を得るべく鋭意研究を重ねた
結果、シアル酸並びにシアル酸誘導体に優れた老化予防
効果を有することを見いだし、本発明を完成するに至っ
た。In view of the above circumstances, the present inventors have conducted intensive research to obtain a drug that is effective against aging phenomena and has a high degree of safety. As a result, the present inventors have found that sialic acid and sialic acid derivatives have excellent anti-aging effects. They discovered this and completed the present invention.
即ち本発明は、シアル酸及びシアル酸誘導体より成る群
から選択された一種又は二種以上を含をしてなる皮膚老
化予防剤を提供するものである。That is, the present invention provides a skin aging preventive agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明に用いられるシアル酸は公知の物質であり、ポリ
ヒドロキシモノアミノカルボン酸(ノイラミン酸)のN
−アシル及び、N−アシル、0−アシル誘導体の総称で
、シアリン酸ともいわれる。The sialic acid used in the present invention is a known substance, and the N of polyhydroxymonoaminocarboxylic acid (neuraminic acid)
It is a general term for -acyl, N-acyl, and O-acyl derivatives, and is also called sialic acid.
シアル酸は、各種の生物に含まれ、通常細胞表層糖質を
構成して糖タン白質や粧・脂質の末端にグリコシド結合
して存在する。特に脳、神経、血液、顧下腺、ムチン質
、初乳に多くは存在するが、遊離して血清や体液、尿中
にも存在する。生物界に一番多く見いだされる代表的な
シアル酸はN−アセデルノイラミン酸(NANA :分
子lit 309)で、融点185〜187°、[α]
菅−32°±2°の白色粉末である。Sialic acid is contained in various living organisms, and usually constitutes cell surface carbohydrates and exists in glycosidic bonds at the terminal ends of glycoproteins, cosmetics, and lipids. Particularly, it exists in large quantities in the brain, nerves, blood, thyroid glands, mucin, and colostrum, but it also exists free in serum, body fluids, and urine. The most typical sialic acid found in the living world is N-acedelneuraminic acid (NANA: molecular lit. 309), with a melting point of 185-187°, [α]
It is a white powder with an angle of -32°±2°.
シアル酸並びにシアル酸誘導体の生物学的薬理作用は細
胞表面の陰性荷電への寄与、細胞の特異的認識機構への
関与、ウィルスによる赤血球凝集反応や血液タン白質の
ホーミング現象等に関することが知られている。最近で
は、シアル酸について、去痰活性(特開昭61−684
18 ) 、抗炎症効果(特開昭62−145015)
並びにシアル酸結合オリゴ糖の栄養効果(特開昭61−
152233)等の報告がなされている。The biological and pharmacological actions of sialic acid and sialic acid derivatives are known to contribute to the negative charge on the cell surface, to participate in specific recognition mechanisms of cells, to cause hemagglutination reactions caused by viruses, and to the homing phenomenon of blood proteins. ing. Recently, sialic acid has been studied for its expectorant activity (Japanese Patent Application Laid-Open No. 61-684
18), anti-inflammatory effect (Japanese Patent Application Laid-Open No. 145015/1983)
and nutritional effects of sialic acid-bonded oligosaccharides (Unexamined Japanese Patent Publication No. 1986-
152233) etc. have been reported.
しかしながら、皮膚老化予防効果をもつことは今だ知ら
れていない。シアル酸並びにシアル酸誘導体の製造法は
合成法、天然抽出法(原料:卵白、顎下腺ムチン、胎盤
エキス、大腸菌から得られるコロミン酸等)等が挙げら
れるが、安価な点から乳原料抽出法(特許第1)912
12 、特許第1253988、特開昭59−1841
97等)の応用が特に好ましい。However, it is not yet known that it has anti-aging effects on the skin. Methods for producing sialic acid and sialic acid derivatives include synthetic methods and natural extraction methods (raw materials: egg white, submandibular gland mucin, placenta extract, colominic acid obtained from Escherichia coli, etc.), but milk raw material extraction is preferred due to its low cost. Law (Patent No. 1) 912
12, Patent No. 1253988, JP-A-59-1841
97 etc.) is particularly preferred.
以下に本発明に係る化合物の乳抽出物による製造例を示
す。乳抽出法で用いる乳は、牛乳、手孔、母乳(人)そ
の他適宜選択できる。又、精製の度合いにより、シアル
酸含有濃度を自由にコントロールできるので用法、用途
、剤型、その他目的に応じて精製すれば良い。尚、製造
法は、これにより限定されるものではない。An example of producing the compound according to the present invention using a milk extract is shown below. The milk used in the milk extraction method can be selected from cow's milk, milk, breast milk (human), and others as appropriate. Furthermore, the concentration of sialic acid can be freely controlled depending on the degree of purification, so the purification can be done according to usage, application, dosage form, and other purposes. Note that the manufacturing method is not limited to this.
(製造例1)シアル酸
チーズホエー10tに塩酸28kgを添加してPHを2
に調整した後92℃で60分間加熱して加水分解を行っ
た。得られたホエーの加水分解液をスクリューデカンタ
−を用いて加熱により凝固したタンパク質を除去してシ
アル酸含有液を得た。次いで、シアル酸含有液を電気透
析装置の脱塩槽に入れて伝導度2 mS/ cmまで脱
塩した酸、−旦透析を中止して濃縮槽液を廃棄した。次
いで濃縮槽に蒸留水30βを入れて再び伝導度50μS
/cmまで透析を行った。透析終了後、濃縮槽液を濃縮
・乾燥して白色粉末600gを得た。このようにして得
られた粉末のM離シアル酸純度は約97%であった。(Production Example 1) Add 28 kg of hydrochloric acid to 10 tons of sialic acid cheese whey to adjust the pH to 2.
After adjusting the temperature, the mixture was heated at 92° C. for 60 minutes to perform hydrolysis. Proteins coagulated by heating were removed from the resulting whey hydrolysis solution using a screw decanter to obtain a sialic acid-containing solution. Next, the sialic acid-containing solution was placed in a desalination tank of an electrodialysis machine, and the acid was desalted to a conductivity of 2 mS/cm.Once the sialic acid-containing solution was desalted, the dialysis was stopped and the concentration tank liquid was discarded. Next, add 30β of distilled water to the concentration tank and increase the conductivity to 50 μS again.
Dialysis was performed to /cm. After the dialysis was completed, the concentration tank liquid was concentrated and dried to obtain 600 g of white powder. The purity of the M-released sialic acid of the powder thus obtained was about 97%.
(製造例2)シアル酸塩
前述の遊離シアル酸を苛性ソーダで調整し、シアル酸N
aを得る。この他、目的に応じてMg塩、k塩、リン酸
塩、アミン塩等を製造することができる。(Production Example 2) Sialic acid salt The free sialic acid mentioned above was adjusted with caustic soda, and sialic acid N
get a. In addition, Mg salts, k salts, phosphates, amine salts, etc. can be produced depending on the purpose.
(!1idJ造例3)シアル酸結合オリゴ糖牛乳或いは
チーズホエーを限外濾過して調製した濾液を、全固形2
0%まで減圧濃縮した。この液25kgを電気伝導度が
20μS/cmになる迄電気透析した後、ダウエックス
IX2(2kg)を充填したカラムに通じてオリゴ糖を
吸着させた。次いでこのカラムに20kgの水を通じて
中性糖を除去した後、0.5M塩酸を通じてカラムに吸
着したオリゴ糖を溶出させた。得られた溶出液のpHを
30%苛性ソーダでpH7,0に調整後、再び電気伝導
度が150μS/cmになる迄電気透析した。得られた
透析液を濃縮・乾燥して白色粉末100gを得た。この
ようにして得た粉末のシアル酸結合オリゴ糖純度は90
%であ −′つだ。(!1idJ Preparation Example 3) The filtrate prepared by ultrafiltration of sialic acid-bonded oligosaccharide milk or cheese whey was
It was concentrated under reduced pressure to 0%. After electrodialyzing 25 kg of this liquid until the electrical conductivity reached 20 μS/cm, it was passed through a column packed with DOWEX IX2 (2 kg) to adsorb oligosaccharides. Next, 20 kg of water was passed through the column to remove neutral sugars, and then the oligosaccharides adsorbed on the column were eluted with 0.5M hydrochloric acid. The pH of the obtained eluate was adjusted to pH 7.0 with 30% caustic soda, and then electrodialyzed again until the electrical conductivity reached 150 μS/cm. The obtained dialysate was concentrated and dried to obtain 100 g of white powder. The purity of the sialic acid-bonded oligosaccharide of the powder thus obtained was 90.
It is −′ one in %.
(製造例4)シアル酸結合タン白
レンネットカゼインカード廃液3001をフォードラタ
ンクで75℃、30分間加熱殺菌した後に、40℃まで
冷却し、濃塩酸でpHを4.6に調整した。約30分間
静置し沈殿を生成させた液をタラリファイヤーに通しp
Hを7.0に戻した後、清澄液をRO膜で濃縮・脱塩し
た。10倍まで濃縮した後、濃縮液に加えて再び10倍
まで濃縮した。得られた粉末のシアル酸結合タン白の純
度は約80%あった。(Production Example 4) Sialic acid-bound protein Rennet Casein Card waste liquid 3001 was heat sterilized at 75°C for 30 minutes in a Fordora tank, then cooled to 40°C, and the pH was adjusted to 4.6 with concentrated hydrochloric acid. Let stand for about 30 minutes to form a precipitate, then pass the solution through a tallifier.
After returning H to 7.0, the clear liquid was concentrated and desalted using an RO membrane. After concentrating to 10 times, it was added to the concentrate and concentrated again to 10 times. The purity of the sialic acid-bound protein in the powder obtained was about 80%.
(!!!造例5)シアル酸脂質
バターミルク粉15kgにクロロホルム−メタノール混
液(1: 1)を1001加え、室温で30分間攪拌し
抽出した。次にクロロホルム−メタノール混液を回収し
イオン交換樹脂(D[EAE−Toyopearlアセ
テート型)1j2に通じてシアル酸結合脂質を吸着させ
、次いでクロロホルム−メタノール混液(1:1)2N
で樹脂を洗浄した後、0.5M酢酸ナトリウム−メタノ
ール溶液(1:1)2j2で樹脂を洗≦ht、た後、0
.釘酢酸ナトリウムーメタノール溶液41でシアル酸結
合脂質を溶出した。溶出液を濃縮しメタノールを除去し
た後、水5gを加えて限外濾過で脱塩とシアル酸結合脂
質の濃縮を行った。(!!!Preparation Example 5) To 15 kg of sialic acid lipid buttermilk powder was added 1,001 liters of a chloroform-methanol mixture (1:1), and the mixture was stirred at room temperature for 30 minutes for extraction. Next, the chloroform-methanol mixture was collected and passed through an ion exchange resin (D [EAE-Toyopearl acetate type) 1j2 to adsorb sialic acid-bound lipids, and then a chloroform-methanol mixture (1:1) 2N
After washing the resin with 0.5M sodium acetate-methanol solution (1:1) 2j2,
.. Sialic acid-bound lipids were eluted with sodium nail acetate-methanol solution 41. After concentrating the eluate to remove methanol, 5 g of water was added and ultrafiltration was performed to desalt and concentrate the sialic acid-bound lipids.
シアル酸結合脂質を含む濃縮液をエバポレータで乾固し
た後、シリカゲルカラム(4,OX 50cm)に通じ
シアル酸結合脂質を吸着させ、次いでクロロホルム1β
、クロロホルム−メタノール混液(4:1)IAで順次
洗浄した後、クロロホルム−メタノール(2: 8)の
混液2I2でシアル酸結合脂質を溶出した。溶出液をエ
バポレータで蒸発乾固し白色粉末15gを得た。After the concentrated solution containing sialic acid-bound lipids was dried in an evaporator, it was passed through a silica gel column (4, OX 50cm) to adsorb the sialic acid-bound lipids, and then chloroform 1β
After sequentially washing with chloroform-methanol mixture (4:1) IA, the sialic acid-bound lipid was eluted with chloroform-methanol (2:8) mixture 2I2. The eluate was evaporated to dryness using an evaporator to obtain 15 g of white powder.
このようにして得られた粉末のシアル酸結合脂質の純度
は薄層クロマトグラフィーで90%以上(レゾルシノー
ル法)であった。The purity of the sialic acid-bound lipid in the powder thus obtained was 90% or more (resorcinol method) as determined by thin layer chromatography.
次にシアル酸及びシアル酸誘導体の安全性試験を実施し
たので、その結果を示す。Next, safety tests were conducted on sialic acid and sialic acid derivatives, and the results are shown below.
急性毒性試験
製造例1〜5で製造したシアル酸、シアル酸N a %
シアル酸結合オリゴ糖、シアル酸結合タン白及びシアル
酸結合脂質各々を被験物質として、ICR系雌性マウス
(6週齢、1群5匹)を用い、腹腔内投与は、0.5%
カルボキシメチルセルロースナトリウム/生理食塩液に
各被験物質2重量%となるように懸濁させたものを22
1/2 Gの注射針を使用して、又、経口投与はオリー
ブ油に各被験物質5重量%となるように懸濁させたもの
を経口針を使用して、腹腔内投与(60mff/kg)
、経口投与(30++!? / kg)を与えた。そ
の結果、全部の被験物質について7日間の観察期間中に
死亡例、体重の減少および特記すべき中毒症状は認めら
れず、また7日目に行った剖検においても何等以上は認
められなかった。Acute toxicity test Sialic acid produced in Production Examples 1 to 5, sialic acid Na%
Sialic acid-bound oligosaccharides, sialic acid-bound proteins, and sialic acid-bound lipids were each used as test substances in ICR female mice (6 weeks old, 5 mice per group), and 0.5% was administered intraperitoneally.
Each test substance was suspended in sodium carboxymethylcellulose/physiological saline solution at a concentration of 2% by weight.
For oral administration, each test substance was suspended in olive oil at a concentration of 5% by weight and administered intraperitoneally using an oral needle (60 mff/kg).
, given orally (30++!?/kg). As a result, no deaths, no decreases in body weight, and no noteworthy toxic symptoms were observed for any of the test substances during the 7-day observation period, and no signs of toxicity were observed in the autopsy conducted on the 7th day.
この結果から明らかなように、シアル酸及びシアル酸誘
導体の急性毒性値(LD50)は、腹腔内投与で、12
00mg/ kg以上、経口投与で1500mg/ k
g以上であり、安全性が高いことが判明した。As is clear from this result, the acute toxicity value (LD50) of sialic acid and sialic acid derivatives is 12
00mg/kg or more, orally 1500mg/k
g or more, indicating high safety.
次にシアル酸並びにシアル酸誘導体を皮膚老化予防剤と
して適用するための製剤化について述べる。Next, we will describe formulations for applying sialic acid and sialic acid derivatives as skin aging preventive agents.
本発明の皮膚老化予防剤は、シアル酸、シアル酸誘導体
の他に製薬上、許容することのできる添加剤及び他の薬
剤を加えた混合物の形で使用できる。但し、シアル酸は
、光、酸、アルカリに対する安定性が悪いため、長期保
存性に問題があり、安定性の点から、シアル酸誘導体を
使用する方が望ましい。The skin aging preventive agent of the present invention can be used in the form of a mixture containing pharmaceutically acceptable additives and other drugs in addition to sialic acid and sialic acid derivatives. However, since sialic acid has poor stability against light, acids, and alkalis, there is a problem in long-term storage, and from the viewpoint of stability, it is preferable to use sialic acid derivatives.
本発明の皮膚老化予防剤には上記した必須成分の他に通
常化粧品や医薬品等に用いられる他の成分、例えばアボ
ガド油、パーム油、ビーナツツ油、牛脂、コメヌカ油、
ホホバ油、カルナバロウ、ラノリン、流動パラフィン、
オキシステアリン酸、パルミチン酸イソステアリル、イ
ソステアリルアルコール等の油分、グリセリン、ソルビ
トール、ポリエチレングリコール、コラーゲン、ヒアル
ロン酸、コンドロイチン硫酸等の保湿剤、パラジメチル
アミノ安息香酸アミル、ウロカニン酸、ジイソブロビル
ケイヒ酸エチル等の紫外線吸収剤、エリソルビン酸ナト
リウム、セージエキス、ビタミンE、パラヒドロキシア
ニソール等の酸化防止剤、ステアリル硫酸ナトリウム、
セチル硫酸ジェタノールアミン、セチルトリメチルアン
モニウムサッカリン、イソステアリン酸ポリエチレング
リコール、アラキン酸グリセリル等の界面活性剤、エチ
ルパラベン、ブチルパラベン等の防腐剤、オウバク、オ
ウレン、シコン、シャクヤク、センブリ、バーチ、ビワ
等の抽出物、グリチルリチン酸誘導体、グリチルレチン
酸誘導体、サリチル酸誘導体、ヒノキチオール、酸化亜
鉛、アラントイン等の消炎剤、胎磐抽出物、グルタチオ
ン、ユキノシタ抽出物、アスコルビン酸誘導体等の美白
剤、ニンジン、アロエ、ゼニアオイ、アイリス、ブドウ
、ヨクイニン、ヘチマ、ユリ等の抽出物、ローヤルゼリ
ー、感光素、コレステロール誘導体、各種アミノ酸類、
ビオチン、パントテン酸誘導体等各種ビタミン類及び誘
導体等の賦活剤、サフラン、センキュウ、ショウキョウ
、オトギリソウ、オノニス、ローズマリー、ニンニク等
の抽出物、T−オリザノール、デキストラン硫酸ナトリ
ウム、ビタミンE誘導体、ニコチン酸誘導体、ニコチン
酸誘導体等の血行促進剤、硫黄、チアントール等の抗脂
漏剤、香料、水、アルコール、カルボキシビニルポリマ
ー等の増粘剤、チタンイエロー、カーサミン、ヘニバナ
赤等の色剤等を必要に応じて適宜配合することができる
。In addition to the above-mentioned essential ingredients, the skin aging prevention agent of the present invention may contain other ingredients commonly used in cosmetics and pharmaceuticals, such as avocado oil, palm oil, peanut oil, beef tallow, rice bran oil,
Jojoba oil, carnauba wax, lanolin, liquid paraffin,
Oils such as oxystearic acid, isostearyl palmitate, isostearyl alcohol, glycerin, sorbitol, polyethylene glycol, collagen, hyaluronic acid, humectants such as chondroitin sulfate, amyl paradimethylaminobenzoate, urocanic acid, diisobrobyl cinnamic acid UV absorbers such as ethyl, sodium erythorbate, sage extract, vitamin E, antioxidants such as parahydroxyanisole, sodium stearyl sulfate,
Surfactants such as cetyl sulfate jetanolamine, cetyl trimethylammonium saccharin, polyethylene glycol isostearate, and glyceryl arachate, preservatives such as ethyl paraben and butyl paraben, and antiseptics such as sucrose, orensis, chicon, peony, Japanese japonica, birch, loquat, etc. Extracts, anti-inflammatory agents such as glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, whitening agents such as fetal rock extract, glutathione, saxifrage extract, ascorbic acid derivatives, carrots, aloe, mallow, Extracts of iris, grape, lily, loofah, lily, etc., royal jelly, photosensor, cholesterol derivatives, various amino acids,
Activators of various vitamins and derivatives such as biotin and pantothenic acid derivatives, extracts of saffron, nebula, ginger, hypericum, ononis, rosemary, garlic, etc., T-oryzanol, dextran sodium sulfate, vitamin E derivatives, nicotinic acid Derivatives, blood circulation promoters such as nicotinic acid derivatives, antiseborrheic agents such as sulfur and thianthol, fragrances, water, alcohol, thickeners such as carboxyvinyl polymer, and coloring agents such as titanium yellow, cursamine, and henibana red are required. It can be blended as appropriate.
本発明の剤型は、薬効を得るに通したものであれば、任
意の形で使用でき、例えば外用剤、粉末、顆粒、散剤、
錠剤、カプセル剤、シロップ剤、生理、注射剤等が挙げ
られる。この中では外用剤が用法上簡便で予防、治療の
両面で好ましく、外用できるものであれば、任意の形態
でよい。The dosage form of the present invention can be used in any form as long as it achieves medicinal effects, such as external preparations, powders, granules, powders, etc.
Examples include tablets, capsules, syrups, physiological preparations, and injections. Among these, external preparations are preferred from the standpoint of both prevention and treatment as they are easy to use, and may be in any form as long as they can be applied externally.
例えばローション、リニメント、乳液等の外用液剤、ク
リーム、軟膏、バスタ、ゼリー、スプレー等の外用半固
型剤等を挙げることができ、皮膚に直接塗布または散布
する経皮投与による投与方法をとる。Examples include external liquid preparations such as lotions, liniments, and emulsions, and external semi-solid preparations such as creams, ointments, baths, jellies, and sprays, and are administered by transdermal administration by directly applying or spraying on the skin.
本発明の皮膚老化予防剤には、有効成分であるシアル酸
及びシアル酸誘導体の一種または二種以上の配合量は、
組成物全重量に対して0.0001〜50重量%、好ま
しくは0.001〜5重量%である。The amount of one or more types of sialic acid and sialic acid derivatives as active ingredients in the skin aging prevention agent of the present invention is as follows:
The amount is 0.0001 to 50% by weight, preferably 0.001 to 5% by weight, based on the total weight of the composition.
0.0001重量%未満では効果が乏しくなる傾向にあ
り、50ffiJi%を越えて配合しても効果の大きな
増大を望むことは難しい。If it is less than 0.0001% by weight, the effect tends to be poor, and even if it is added in excess of 50ffiJi%, it is difficult to expect a significant increase in the effect.
本発明の皮膚老化予防剤の投与量は、年齢、個人差、症
状等によって下記範囲外の量を役することもあり得るの
で、明確には規定できないが、−般にシアル酸及びシア
ル酸誘導体の一種または二種以上の内服及び経皮投与量
は体重IKg及び1日あたり0.0001〜2000m
g、好ましくは0.001〜200mgでありこの量を
1日に1回または数回に分けて投与することができる。The dosage of the skin aging preventive agent of the present invention cannot be clearly defined because the amount may be outside the following range depending on age, individual differences, symptoms, etc. Oral and transdermal administration of one or more of
g, preferably 0.001 to 200 mg, and this amount can be administered once a day or in divided doses.
又、シアル酸並びにシアル酸誘導体の配合濃度及び目的
とする効果の度合いにより、医薬品、医薬部外品、化粧
品類更には老化の予防の目的に食品としても応用できる
。Furthermore, depending on the blending concentration of sialic acid and sialic acid derivatives and the degree of desired effect, it can be applied to pharmaceuticals, quasi-drugs, cosmetics, and even foods for the purpose of preventing aging.
[実施例]
以下、本発明の優れた効果を明らかにするため、実施例
および比較例を用いて評価試験を行った。[Example] In order to clarify the excellent effects of the present invention, evaluation tests were conducted using Examples and Comparative Examples.
尚、本発明はこれにより限定されるものではない。Note that the present invention is not limited to this.
(試験方法)
(1) モルモット皮膚を用いた表皮のターンオーア
ルピノモルモットを1群5匹とし6群に分けて評価に用
いた。モルモットの腹部皮膚を刺毛後、螢光色素である
ダンジルクロライドを5重量%配合した白色ワセリン軟
膏を0.1 J/cn、 24時間、閉塞塗布した。被
験物質は実施例1〜5および比較例1を1日1回0.3
mffずつダンジルクロライド塗布部に宙ね塗りし、皮
膚の角質層ターンオーバー速度はダンジルクロライドが
消失するまでの口数をもって評価した。(Test method) (1) Epidermal turnover using guinea pig skin Alpino guinea pigs were divided into 6 groups of 5 animals per group and used for evaluation. After pricking the abdominal skin of the guinea pig, a white petrolatum ointment containing 5% by weight of the fluorescent dye danzyl chloride was applied in an occluded manner at 0.1 J/cn for 24 hours. The test substance was 0.3% of Examples 1 to 5 and Comparative Example 1 once a day.
mff was applied onto the area to which Danzyl chloride was applied, and the turnover rate of the stratum corneum of the skin was evaluated by the number of applications until Danzyl chloride disappeared.
(2)乾燥性疾患の治療効果測定方法
40〜60才の老人性乾皮症患者女性30名を被験者と
し、1群5名で6群にわけ、右頬に薬剤配合の実施例1
〜5あるいは比較例1を塗布し、人頼には対照として薬
剤無配合の比較例2を塗布させた。(2) Method for measuring the therapeutic effect of dryness disease Example 1: 30 female patients aged 40 to 60 years old with senile xeroderma were divided into 6 groups of 5 people per group, and the drug was administered on the right cheek.
5 or Comparative Example 1, and as a control, Comparative Example 2 containing no drug was applied to Hitoyori.
試験期間は冬期の1力月とし、被験物質をそれぞれ10
2回2mlずつ朝晩塗布した。30日間の塗布が終了し
た時点で、人頼に比べて右頬の改善効果を医者に判定し
てもらった。The test period was one month in winter, and 100% of each test substance was used.
It was applied twice, 2 ml each in the morning and at night. At the end of 30 days of application, a doctor evaluated the improvement effect on the right cheek compared to Hitoyori.
(3)疲労したヒト皮膚の賦活効果の測定方法睡眠不足
により肌あれ、色の黒ずみ、皮膚のつや、はりの消失等
が生じる。特にこれらの症状が顕著に生じる冬期におい
て、疲労した皮膚に対する被験物質の即効的皮膚賦活効
果を評価した。30代の女性30名を被験者として、1
群5名で、6群に分け、右頬に実施例1〜5或いは比較
例1を塗布し、人頼は無塗布とした。試験期間は冬期の
2日間とし、被験物質をそれぞれ2−ずつ1日2回2日
間朝及び寝る前に、塗布し、試験終了後に、試験前の肌
に比べて、試験後の肌の状態について被験者に自己採点
してもらった。(3) Method for measuring the revitalizing effect on tired human skin Lack of sleep causes skin roughness, darkening of the skin, and loss of skin luster and firmness. We evaluated the immediate skin revitalizing effect of the test substance on tired skin, especially in the winter when these symptoms are most noticeable. 1 with 30 women in their 30s as subjects.
There were 5 people in the group, divided into 6 groups, and Examples 1 to 5 or Comparative Example 1 were applied to the right cheek, while Hitoyori was left unapplied. The test period was 2 days in winter, and 2 doses of each test substance were applied twice a day for 2 days in the morning and before going to bed.After the test, the condition of the skin after the test was compared to the skin before the test. Subjects were asked to self-score.
但し、試験20間中、被験者は、明は方4時に床につき
朝7時に起床(睡眠時間3時間)し、それ以外の仮眠は
とらないものとする。However, during the 20 tests, the test subjects were to go to bed at 4am in the morning and wake up at 7am (sleep time 3 hours), and take no other naps.
−計価項目一
■肌荒れ度合、■肌のくすみ、■肌のきめ、■化粧のり
、■肌のつや、はり、たるみ−採点−
5点:試験前と比べて顕著に改善された。-Measurement items 1 ■ Degree of skin roughness, ■ Skin dullness, ■ Skin texture, ■ Makeup paste, ■ Skin gloss, firmness, and sagging - Scoring - 5 points: Significantly improved compared to before the test.
4点: やや改善された。4 points: Slightly improved.
3点: 変化なし。3 points: No change.
2点: やや悪化した。2 points: Slightly worsened.
1点: 顕著に悪化した。1 point: Significantly worsened.
(4) ヒト皮膚による老化予防効果のトリ定方法2
5〜50才の女性30名を被験者として、1群5名で6
群に分け、右頬に実施例1〜5、比較例1を使用、人頼
には薬剤無配合の比較例2を使用させた。試験期間は冬
期2力月間、1日2回朝及び夜の連続塗布とし、下記(
a)〜(e)にて効果を評価した。(4) Method 2 for determining anti-aging effects on human skin
The subjects were 30 women aged 5 to 50, with 5 women per group and 6
They were divided into groups, and Examples 1 to 5 and Comparative Example 1 were used on the right cheek, while Comparative Example 2, which did not contain any drug, was used on the right cheek. The test period was two months of winter, with continuous application twice a day in the morning and evening.
The effects were evaluated in a) to (e).
(Ill) 皮19表面形態の評価
下記の基準に従って皮膚乾燥度を肉眼的に判定すること
により皮19表面形態を評価した。(Ill) Evaluation of skin 19 surface morphology The skin 19 surface morphology was evaluated by visually determining the degree of skin dryness according to the following criteria.
−判定方法− 著効:比較例2と比べて乾燥、落せつがほとんどない。-Judgment method- Remarkable effect: Compared to Comparative Example 2, there is almost no drying or flaking.
有効:比較例2と比べて乾燥、落せつが少ない。Effective: Less drying and peeling than Comparative Example 2.
やや有効:比較例2と比べて乾燥は同程度であるが、落
せつがない。Slightly effective: Drying is the same as in Comparative Example 2, but it is not easy to remove.
無効:比較例2と比べて乾燥、落せつに差がない。Ineffective: There is no difference in drying and peeling compared to Comparative Example 2.
悪化:比較例2と比べて乾燥、落せつが著しい。Deterioration: Compared to Comparative Example 2, dryness and flaking are significant.
(b) 皮膚外観の観察
外観の美しさを、上記被験者について皮膚レプリカをシ
リコン樹脂を用いて採取し、実体顕i鏡で観察すること
により評価した。(b) Observation of skin appearance The beauty of the skin appearance was evaluated by collecting skin replicas of the above subjects using silicone resin and observing them with a stereoscopic microscope.
一判定方法一
著効:比較例2と比べて皮溝や皮丘が著しく鮮明で整っ
ている。1. Judgment method 1. Remarkable effectiveness: Compared to Comparative Example 2, the skin grooves and skin mounds are significantly clearer and more regular.
有効:比較例2と比べて皮溝や皮丘がやや明瞭に整って
いる。Effective: Compared to Comparative Example 2, the skin grooves and skin mounds are slightly more clearly arranged.
無効:比較例2と比べて差が認められない。Invalid: No difference compared to Comparative Example 2.
悪化:比較例2と比べて皮溝や皮丘が不鮮明。Deterioration: Compared to Comparative Example 2, skin grooves and skin mounds are unclear.
(C1角質層の機能の評価
TWL (Trans−epidermal Wate
r Loss:経表皮性水分損失)を測定することによ
り、角質層の機能を評価した。TWLはエバポリメータ
ーEPL(スウェーデンSerνo Med、社製)を
用いて測定した。(Evaluation of the function of the C1 stratum corneum TWL
The function of the stratum corneum was evaluated by measuring rLoss (transepidermal water loss). TWL was measured using Evapolymeter EPL (manufactured by Sernuo Med, Sweden).
一判定方法一 著効:比較例2と比べてTWLが30%以上減少。1. Judgment method 1. Significant effect: TWL decreased by 30% or more compared to Comparative Example 2.
宥効:比較例2と比べてTWLが10%以上減少。Soothing effect: TWL decreased by 10% or more compared to Comparative Example 2.
無効:比較例2と比べてTWLが10%未満。Ineffective: TWL is less than 10% compared to Comparative Example 2.
悪化:比較例2と比べてTWLが10%以上増大。Deterioration: TWL increased by 10% or more compared to Comparative Example 2.
(dl 剥離角質細胞の評価
評価試験前後の被験部皮膚にスコッチテープにチバンメ
ンディングテープ)を接着し、これを剥離した後、テー
プについた角質細胞をHE染色し細胞内の核の有無を顕
微鏡にて判定した。(dl Evaluation of exfoliated keratinocytes) Apply Scotch tape to Tiban mending tape to the skin of the test subject before and after the evaluation test. After peeling off the tape, the keratinocytes attached to the tape are stained with HE and the presence or absence of nuclei within the cells is examined using a microscope. Judgment was made.
−判定方法−
正常:核がまったく認められず正常な角質化が起こって
いる。-Judgment method- Normal: No nuclei are observed and normal keratinization occurs.
異常:核が認められ異常な角質化が起きている。Abnormal: Nuclei are observed and abnormal keratinization occurs.
(e) 官能評価
試験終了後、人頼(比較例2)に比べて右頼の肌状態に
ついて被験者に自己採点してもらった。(e) After the sensory evaluation test was completed, the subjects were asked to self-rate the skin condition of Uyori compared to Hitoyori (Comparative Example 2).
−計価項目一
■小じわ、■肌のきめ、■肌のくすみ、■ 肌のたるみ
、つや、はり、■化粧のり一採点−
5点:比較例2に比べて顕著に改善された。-Measurement items 1 ■Fine wrinkles, ■Skin texture, ■Skin dullness, ■Skin sagging, luster, firmness, ■Makeup paste1 Score- 5 points: Significantly improved compared to Comparative Example 2.
4点: やや改善された。4 points: Slightly improved.
3点: 変化なし。3 points: No change.
2点: 〃 やや悪化した。2 points: Slightly worsened.
1点: 顕著に悪化した。1 point: Significantly worsened.
比較例2は、比較例1からビタミンEアセテートを精製
水におきかえた薬剤無配合の処方とする。Comparative Example 2 is a drug-free formulation in which vitamin E acetate was replaced with purified water from Comparative Example 1.
(以下余白)
(試験結果)
(1)表−2の結果から明らかなように、モルモットを
用いた評価により、シアル酸又はシアル酸誘導体を含有
する実施例1〜5は比較例1と比べて表皮のターンオー
バーを2〜3日間速めていることが認められ、更には二
種類以上組み合せることにより、相乗効果が得られるこ
とがわかった。(Left below) (Test results) (1) As is clear from the results in Table 2, the evaluation using guinea pigs showed that Examples 1 to 5 containing sialic acid or sialic acid derivatives were superior to Comparative Example 1. It was observed that epidermal turnover was accelerated for 2 to 3 days, and furthermore, it was found that a synergistic effect can be obtained by combining two or more types.
表−2表皮のターンオーバー速度試験結果(2)表−3
の結果から実施例1〜5は比較例1に比べて老人性乾皮
症に有効であることが認められた。更には、シアル酸及
びシアル酸誘導体から二種以上を組合せることによって
相乗的効果が得られることも認められた。Table-2 Epidermal turnover speed test results (2) Table-3
From the results, Examples 1 to 5 were found to be more effective against senile xeroderma than Comparative Example 1. Furthermore, it has been found that a synergistic effect can be obtained by combining two or more types of sialic acid and sialic acid derivatives.
表−3老人性乾皮症治療効果試験の結果(3)表−4の
結果から、実施例1〜5は、比較例1に比べて疲労した
皮膚に対して即効的皮膚賦活効果があること並びにシア
ル酸及びシアル酸誘導体の2種以上の組合せにより相乗
効果が得られることが認められた。Table 3 Results of senile xeroderma therapeutic efficacy test (3) From the results in Table 4, Examples 1 to 5 have an immediate skin revitalizing effect on tired skin compared to Comparative Example 1. It has also been found that a synergistic effect can be obtained by combining two or more types of sialic acid and sialic acid derivatives.
表−4疲労皮膚に対する皮膚賦活効果試験結果(4)表
−5の結果から、肉眼的、レプリカ、TWL、官能のい
ずれの評価においても、実施例が比較例1に比べて有効
であること並びにシアル酸及びシアル酸誘導体の組合せ
が相乗効果を有することが認められた。(dlの結果は
、表皮のターンオーバーの促進作用が異常な角質化によ
り起こるものではないことがわかる。Table 4 Skin revitalization effect test results for fatigued skin (4) From the results in Table 5, the Example is more effective than Comparative Example 1 in any of the macroscopic, replica, TWL, and sensory evaluations. It has been found that the combination of sialic acid and sialic acid derivatives has a synergistic effect. (The dl results show that the promotion of epidermal turnover is not caused by abnormal keratinization.
表−5ヒト皮膚による老化予防効果試験結果次に各種実
施態様を示す。以下、配合量は重量%とする。Table 5 Results of anti-aging effect test on human skin Next, various embodiments are shown. Hereinafter, the blending amount is expressed as weight %.
実施例6 乳液 次の処方に従い、常法により乳液を製造した。Example 6 Emulsion A milky lotion was produced by a conventional method according to the following recipe.
ステアリン酸 2.0(%)
セフノール 1.0ワセリ
ン 3.0ラノリンアル
コール 2.0流動パラフイン
8.0スクワラン
3.0エスカロール507
2.0シアル酸ナトリウム 0
.001POE (10)モノオレート
2.5トリエタノールアミン 1
.0プロピレングリコール 5.0防腐
剤 通量香料
I
蒸留水 残余実施例7
栄養クリーム
次の処方に従い、常法により栄養クリームを製造した。Stearic acid 2.0 (%)
Cefnol 1.0 Vaseline 3.0 Lanolin Alcohol 2.0 Liquid Paraffin
8.0 Squalane
3.0 Escarole 507
2.0 Sodium sialate 0
.. 001POE (10) Monooleate
2.5 Triethanolamine 1
.. 0 Propylene Glycol 5.0 Preservatives Percent Fragrance
I Distilled water Remaining Example 7
Nutritional Cream A nutritional cream was prepared by a conventional method according to the following recipe.
ステアリン酸 2.0(%ステ
アリルアルコール 7.0還元ラノリン
2.0スクワラン
5.0オクチルドデカノール
6.0POE(25)セチルエーテル
3.0グリセリルモノステアレート2.0
プロピレングリコール 5.0シアル酸
結合オリゴ糖 1.0シアル酸結合タ
ン白 1.0防腐剤
通量香料 通量
蒸留水 残余実施例8
バンク
次の処方に従い、常法によりパンクを製造した。Stearic acid 2.0 (% stearyl alcohol 7.0 reduced lanolin 2.0 squalane
5.0 octyldodecanol
6.0POE(25) Cetyl ether
3.0 Glyceryl monostearate 2.0 Propylene glycol 5.0 Sialic acid-bound oligosaccharide 1.0 Sialic acid-bound protein 1.0 Preservative
Percentage fragrance Percentage distilled water Remaining Example 8
Punctures were manufactured by a conventional method according to the following recipe.
カオリン 67.5 (
%)タルク 19.0プ
ロピレングリコール 7.5酢酸カルシ
ウム 0.01)尿素
0.5
シアル酸結合脂質 5.0香料
0.49
実施例9 リップトリートメント
常法に従って以下の処方のリップ1−リートメントを製
造した。Kaolin 67.5 (
%) Talc 19.0 Propylene glycol 7.5 Calcium acetate 0.01) Urea
0.5 Sialic acid-bound lipid 5.0 Flavor
0.49 Example 9 Lip Treatment A lip 1-treatment having the following formulation was manufactured according to a conventional method.
キャンデリラロウ 9.0 (O
A)固形パラフィン 8.0ミツ
ロウ 5.0カルナバロウ
5・0ラノリン
1).0シアル酸結合オリゴ糖
0.2イソプロピルミリステー1−
10.0香料 適量
酸化防止剤 通量ヒマシ油
残余実施例10 軟 膏
常法に従って以下の処方の軟膏を製造した。Candelilla Row 9.0 (O
A) Solid paraffin 8.0 Beeswax 5.0 Carnauba wax 5.0 Lanolin
1). 0 sialic acid-linked oligosaccharide
0.2 isopropyl myristate 1-
10.0 Fragrance Appropriate amount Antioxidant Appropriate amount Castor oil
Remaining Example 10 Ointment An ointment having the following formulation was manufactured according to a conventional method.
ステアリルアルコール 18.0モクロウ
20.0シアル酸結合タ
ン白 0.5ポリオキシエチレン
モノオレイン酸エステル 0.25グリセリンモノ
ステアリン酸エステル 0.25ワセリン
40.0精製水
残余〔発明の効果〕
本発明の皮1■老化予防剤は皮膚老化予防効果(荒肌改
善、角質改善、表皮のターンオーバー促進、皮膚のくす
み、たるみ、はり、つや、硬化の改善、皮膚賦活効果、
保湿効果)に優れ、安定性、安全性及び使用性に優れた
ものである。Stearyl alcohol 18.0 Japanese blackberry 20.0 Sialic acid-bonded protein 0.5 Polyoxyethylene monooleate 0.25 Glycerin monostearate 0.25 Vaseline
40.0 Purified water
Residual [Effects of the Invention] Skin 1 of the present invention Anti-aging agent has skin anti-aging effects (improving rough skin, improving keratin, promoting epidermal turnover, improving skin dullness, sagging, firmness, luster, and hardening, and revitalizing the skin. effect,
It has excellent moisturizing effect), stability, safety and usability.
Claims (4)
された一種又は二種以上を含有してなる皮膚老化予防剤
。(1) A skin aging prevention agent containing one or more selected from the group consisting of sialic acid and sialic acid derivatives.
酸結合タン白、シアル酸結合脂質並びにシアル酸塩であ
る特許請求の範囲第(1)項記載の皮膚老化予防剤。(2) The skin aging prevention agent according to claim (1), wherein the sialic acid derivative is a sialic acid-bonded oligosaccharide, a sialic acid-bonded protein, a sialic acid-bound lipid, or a sialic acid salt.
導体を用いる特許請求の範囲第(1)項又は第(2)項
記載の皮膚老化予防剤。(3) The skin aging prevention agent according to claim (1) or (2), which uses sialic acid or a sialic acid derivative obtained by extraction from milk.
請求の範囲第(1)項、第(2)項又は第(3)項記載
の皮膚老化予防剤。(4) The skin aging preventive agent according to claim (1), (2) or (3), wherein the sialic acid is N-acetylneuraminic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32356887A JP2557240B2 (en) | 1987-12-21 | 1987-12-21 | Skin anti-aging agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32356887A JP2557240B2 (en) | 1987-12-21 | 1987-12-21 | Skin anti-aging agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01163110A true JPH01163110A (en) | 1989-06-27 |
JP2557240B2 JP2557240B2 (en) | 1996-11-27 |
Family
ID=18156151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP32356887A Expired - Lifetime JP2557240B2 (en) | 1987-12-21 | 1987-12-21 | Skin anti-aging agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2557240B2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679645A (en) * | 1993-07-23 | 1997-10-21 | Snow Brand Milk Products Co., Ltd. | Sialic acid powder and process for the preparation thereof |
JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
WO2007110191A1 (en) * | 2006-03-23 | 2007-10-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method and device for electrostatically fixing substrates having a conductive layer |
JP2010006844A (en) * | 2007-08-27 | 2010-01-14 | Iriya Cosmetics Co Ltd | Secretagogue for insulin-like growth factor-1 |
USRE41278E1 (en) * | 1999-01-08 | 2010-04-27 | Yu Ruey J | N-acetyl aldosamines and related N-acetyl compounds, and their topical use |
WO2010150738A1 (en) * | 2009-06-23 | 2010-12-29 | コンビ株式会社 | Agent for preventing reduction in production of collagen, and external composition for skin and cosmetic each comprising same |
WO2010150737A1 (en) * | 2009-06-23 | 2010-12-29 | コンビ株式会社 | Collagen production enhancer, and external composition for skin and cosmetic each comprising same |
WO2011115088A1 (en) * | 2010-03-15 | 2011-09-22 | コンビ株式会社 | Human dermal epithelial cell growth promoter, and skin composition for external use and cosmetic material including the same |
JP2014159490A (en) * | 2014-06-09 | 2014-09-04 | Combi Corp | Agent for promoting the production of collagen, and external composition for skin and cosmetic each containing the same |
JP2014159491A (en) * | 2014-06-09 | 2014-09-04 | Combi Corp | Agent for preventing reduction in production of collagen, and external composition for skin and cosmetic each containing the same |
CN104083291A (en) * | 2014-06-16 | 2014-10-08 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid monomer or its hydrate in cosmetics |
EP3067040A1 (en) | 2015-03-13 | 2016-09-14 | Kialab S.r.l. | Mixture of active ingredients for compositions for cosmetic use |
CN110075054A (en) * | 2019-06-06 | 2019-08-02 | 山东天源人乳库科技发展有限公司 | A kind of humanized's growth factor preparation for repairing and preparation method thereof from human milk |
WO2021167016A1 (en) * | 2020-02-18 | 2021-08-26 | 株式会社ファーマフーズ | Vitelline membrane- and/or chalaza-derived cosmetic composition, and method for producing same |
CN115515558A (en) * | 2020-05-25 | 2022-12-23 | 静冈县公立大学法人 | Elastin production promoter and skin cosmetic |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102204367B1 (en) * | 2014-07-16 | 2021-01-19 | 주식회사 엘지생활건강 | Cosmetic compositions for improving skin wrinkle |
-
1987
- 1987-12-21 JP JP32356887A patent/JP2557240B2/en not_active Expired - Lifetime
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679645A (en) * | 1993-07-23 | 1997-10-21 | Snow Brand Milk Products Co., Ltd. | Sialic acid powder and process for the preparation thereof |
USRE41278E1 (en) * | 1999-01-08 | 2010-04-27 | Yu Ruey J | N-acetyl aldosamines and related N-acetyl compounds, and their topical use |
USRE41339E1 (en) * | 1999-01-08 | 2010-05-18 | Tristrata, Inc. | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use |
USRE44302E1 (en) | 1999-01-08 | 2013-06-18 | Ruey J. Yu | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use |
USRE42902E1 (en) | 1999-01-08 | 2011-11-08 | Tristrata, Inc. | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use |
JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
WO2007110191A1 (en) * | 2006-03-23 | 2007-10-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method and device for electrostatically fixing substrates having a conductive layer |
JP2010006844A (en) * | 2007-08-27 | 2010-01-14 | Iriya Cosmetics Co Ltd | Secretagogue for insulin-like growth factor-1 |
WO2010150738A1 (en) * | 2009-06-23 | 2010-12-29 | コンビ株式会社 | Agent for preventing reduction in production of collagen, and external composition for skin and cosmetic each comprising same |
JP2011006331A (en) * | 2009-06-23 | 2011-01-13 | Combi Corp | Collagen production promoter, and external composition for skin and cosmetic, containing the same |
JP2011006332A (en) * | 2009-06-23 | 2011-01-13 | Combi Corp | Agent for preventing reduction in production of collagen, and external composition for skin and cosmetic each containing the same |
CN107334718A (en) * | 2009-06-23 | 2017-11-10 | 康贝株式会社 | Collagen, which produces, to be reduced inhibitor, the composition for external application and cosmetics for reducing inhibitor is produced comprising the collagen |
WO2010150737A1 (en) * | 2009-06-23 | 2010-12-29 | コンビ株式会社 | Collagen production enhancer, and external composition for skin and cosmetic each comprising same |
WO2011115088A1 (en) * | 2010-03-15 | 2011-09-22 | コンビ株式会社 | Human dermal epithelial cell growth promoter, and skin composition for external use and cosmetic material including the same |
JP2011190217A (en) * | 2010-03-15 | 2011-09-29 | Combi Corp | Human epidermal cell growth promoter, and skin care composition for external use and cosmetic each containing the same |
JP2014159490A (en) * | 2014-06-09 | 2014-09-04 | Combi Corp | Agent for promoting the production of collagen, and external composition for skin and cosmetic each containing the same |
JP2014159491A (en) * | 2014-06-09 | 2014-09-04 | Combi Corp | Agent for preventing reduction in production of collagen, and external composition for skin and cosmetic each containing the same |
CN104083291A (en) * | 2014-06-16 | 2014-10-08 | 武汉中科光谷绿色生物技术有限公司 | Application of N-acetylneuraminic acid monomer or its hydrate in cosmetics |
EP3067040A1 (en) | 2015-03-13 | 2016-09-14 | Kialab S.r.l. | Mixture of active ingredients for compositions for cosmetic use |
CN110075054A (en) * | 2019-06-06 | 2019-08-02 | 山东天源人乳库科技发展有限公司 | A kind of humanized's growth factor preparation for repairing and preparation method thereof from human milk |
WO2021167016A1 (en) * | 2020-02-18 | 2021-08-26 | 株式会社ファーマフーズ | Vitelline membrane- and/or chalaza-derived cosmetic composition, and method for producing same |
JPWO2021167016A1 (en) * | 2020-02-18 | 2021-08-26 | ||
CN115515558A (en) * | 2020-05-25 | 2022-12-23 | 静冈县公立大学法人 | Elastin production promoter and skin cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JP2557240B2 (en) | 1996-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100929264B1 (en) | External skin preparation | |
JP2557240B2 (en) | Skin anti-aging agent | |
JP3923226B2 (en) | Topical skin preparation | |
JP2012041302A (en) | Skin cosmetic | |
JP4813690B2 (en) | Filaggrin synthesis promoter, stratum corneum moisturizing function improving / enhancing agent and stratum corneum free amino acid content increasing agent | |
JPH09291011A (en) | Composition suitable for eternal use | |
TW201907902A (en) | External composition | |
JPH06279227A (en) | Dermatic external preparation and cosmetic | |
JP4430770B2 (en) | Skin elasticity improver | |
JP2684179B2 (en) | Anti-inflammatory agent | |
JP3881411B2 (en) | Composition suitable for external use | |
JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
JPH05262635A (en) | Dermatic external preparation | |
JP2009073806A (en) | Insulin-like growth factor-1 secretagogue | |
JP2555389B2 (en) | Hair restorer | |
JP5226200B2 (en) | Sulfated glycosaminoglycan production promoter and skin external preparation containing the same | |
JP3507635B2 (en) | Composition suitable for external use | |
JPH01117815A (en) | External preparation for skin | |
FR2735982A1 (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING AN EXTRACT OF PLANTS OF THE GENUS FILICIUM | |
JPH10175868A (en) | Water (of chinese medicine idea) improving composition | |
JP5429851B2 (en) | Active oxygen scavenger, skin external preparation and cosmetic using the active oxygen scavenger | |
JP2557241B2 (en) | Anti-pigmenting agent | |
CN106913515B (en) | Taurine-chelated calcium external preparation for reestablishing skin barrier steady state and application thereof | |
JP2008247787A (en) | External preparation for skin | |
EP1231927A2 (en) | Nontoxic vernix compositions and method of producing |